AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Precipio, Inc.
Video analysis: PRPO
All videosNo video analysis for this stock yet. Request one from our team.
News: PRPO
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Precipio Announces Q2-2026 Financial Results
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position
Precipio (NASDAQ:PRPO) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?
Precipio, Inc. (NASDAQ: PRPO - Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $25.12 and traded as low as $20.20. Precipio shares last traded at $21.65, with a volume of 21,130 shares trading hands. Analysts Set New Price Targets A number of
Precipio Announces Q2-2026 Shareholder Update Call
NEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET.
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.
Similar companies
-
Longduoduo Company Limited
LDDD
·
Other OTC
Compare
-
Apimeds Pharmaceuticals US, Inc
APUS
·
New York Stock Exchange Arca
Compare
-
Modular Medical, Inc.
MODD
·
NASDAQ
Compare
-
Vicarious Surgical Inc.
RBOT
·
Other OTC
Compare
-
Pluri Inc.
PLUR
·
NASDAQ
Compare
-
Milestone Scientific Inc.
MLSS
·
New York Stock Exchange Arca
Compare